州级娱乐用大麻合法化后精神病性障碍患者的大麻使用变化
该研究基于美国全国代表性纵向队列2014—2022年数据,纳入1856名有精神病性障碍终生史的成人,采用双重差分法比较RCL州与对照州。
要点
- RCL后精神病性障碍患者30天大麻使用率增加9.53个百分点。
- 敏感性分析显示仅在零售店开业后出现显著增加。
- 高频使用未见显著变化。
核心结论
- 在RCL州,精神病性障碍患者当前大麻使用大幅增加,且增幅大于既往一般人群报告。
- 鉴于大麻可负面影响疾病进程和医疗服务利用,政策制定者应考虑税收、效力、广告和健康警示等监管措施。
研究设计与样本
- 使用2014—2022年Population Assessment of Tobacco and Health全国代表性纵向队列数据,随访5年。
- 样本为1856名18岁及以上有精神病性障碍终生史的美国成人,共贡献7465次应答。
- 采用双重差分法比较RCL州与对照州30天大麻使用率的百分点变化。
主要发现
- 样本平均年龄36.6岁(SD 14.8),50.2%白人,58.2%女性,30天大麻使用率为31.8%。
- 敏感性分析显示零售店开业后出现显著估计,开业前无显著变化。
- 更高频率使用未见显著变化。
临床怎么用
- 对精神病性障碍患者应评估大麻使用,尤其在RCL州。
- 政策制定者可考虑税收、效力、广告和健康警示等监管措施以减少该人群大麻使用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Many individuals can use cannabis without harm, but individuals with psychosis are particularly vulnerable to negative effects from cannabis. No studies to date have investigated how recreational cannabis legalization (RCL) affects cannabis use in individuals with psychosis. OBJECTIVE: To assess impacts of RCL in cannabis use among individuals who have ever been diagnosed with a psychotic illness or episode in the US. DESIGN, SETTING, AND PARTICIPANTS: This study used data from 2014 to 2022 on state-level RCL with 5 years of follow-up from the Population Assessment of Tobacco and Health, a nationally representative longitudinal cohort study of 1856 adults aged 18 years and older in the US. The study sample consisted of individuals with a lifetime history of psychosis. Data were analyzed between January and June 2025. MAIN OUTCOMES AND MEASURES: Percentage point (pp) changes in 30-day use of cannabis after RCL compared with control states using difference-in-differences methods. RESULTS: The study sample consisted of 1856 individuals, with a mean age of 36.6 years (SD, 14.8 years) contributing 7465 responses, and was 50.2% White, 58.2% female, and had a 30-day cannabis-use rate of 31.8%. Individuals with psychosis in RCL states significantly increased their 30-day cannabis use by 9.53 pp (95% CI, 3.05-16.00 pp; P = .004), with sensitivity analyses showing significant estimates after retail outlets opened but not before, and no changes in higher frequency use. CONCLUSIONS AND RELEVANCE: In this study, individuals with psychosis reported a large increase in current cannabis use following legalization and commercialization of cannabis in their state, and by larger amounts than previously reported estimates of the general population. Given how cannabis can negatively affect illness course and health service utilization in individuals with psychosis, these results should be considered by regulators designing policies around taxation, potency, advertising, and health warnings.
引用
- Hyatt AS, Flores MW, Johnson J, et al. Cannabis Use Among Individuals With Psychosis After State-Level Commercial Cannabis Legalization. JAMA Psychiatry. 2026. PMID: 41060643. doi:10.1001/jamapsychiatry.2025.2539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。